Intrapleural administration of pemetrexed : A pharmacokinetic study in an animal model

Journal of Thoracic Oncology

Volumn 4, Issue 3, 2009, Pages 404-408

  Greillier, Laurent ^a   Monjanel Mouterde, Suzanne ^a,b   Fraticelli, Anne ^a   Devictor Pierre, Bénédicte ^b   Bouvenot, Julien ^a   Coltel, Nicolas ^a   Lamarche, Gérald ^b   Astoul, Philippe ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b TIMONE HOSPITAL   (France)

Author keywords

Chemotherapy; Intrapleural administration; Mesothelioma; Pharmacokinetics; Toxicity

Indexed keywords

PEMETREXED; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; ANIMAL MODEL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; INTRALESIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONPARAMETRIC TEST; PLEURA; PROBABILITY; RANDOMIZATION; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUTAMATES; GUANINE; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRALESIONAL; LINEAR MODELS; MALE; MODELS, ANIMAL; PLEURA; PROBABILITY; RANDOM ALLOCATION; RATS; RATS, WISTAR; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC;

EID: 67049109733     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318197f302     Document Type: Article

References (17)

1. Berghmans T, Paesmans M, Lalami Y, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002;38:111-121. (Pubitemid 35157753)
2. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d]pyrimidine- based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-1123.
3. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21: 2636-2644. (Pubitemid 46606305)
4. Rinaldi DA, Kuhn JG, Burris HA, et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 1999;44:372-380.
5. McDonald AC, Vasey PA, Adams L, et al. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res 1998;4:605-610. (Pubitemid 28193558)
6. Rinaldi DA, Burris HA, Dorr FA, et al. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 1995; 13:2842-2850.
7. Takimoto CH. Antifolates in clinical development. Semin Oncol 1997; 24:S18-40-S18-51.
8. Monjanel-Mouterde S, Frenay C, Catalin J, Boutin C, Durand A, Astoul P. Pharmacokinetics of intrapleural cisplatin for the treatment of malignant pleural effusions. Oncol Rep 2000;7:171-175.
9. Perez-Soler R, Lopez-Berestein G, Lautersztain J, et al. Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoatotrans- R,R-1,2-diaminocyclohexane platinum(II). Cancer Res 1990;50: 4254-4259. (Pubitemid 20225660)
10. Lerza R, Vannozzi MO, Tolino G, et al. Carboplatin and cisplatin pharmacokinetics after intrapleural combination treatment in patients with malignant pleural effusion. Ann Oncol 1997;8:385-391. (Pubitemid 27230981)
11. Holoye PY, Jeffries DG, Dhingra HM, et al. Intrapleural etoposide for malignant effusion. Cancer Chemother Pharmacol 1990;26:147-150.
12. Perng RP, Wu MF, Lin SY, Chen YM, Lin JY, Whang-Peng J. A phase I feasibility and pharmacokinetic study of intrapleural paclitaxel in patients with malignant pleural effusions. Anticancer Drugs 1997;8: 565-573. (Pubitemid 27373435)
13. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966;50: 219-244.
14. Pestieau SR, Stuart OA, Sugarbaker PH. Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model. Eur J Surg Oncol 2000;26:696-700.
15. Pretorius RG, Petrilli ES, Kean CK, Ford LC, Hoeschele JD, Lagasse LD. Comparison of the iv and ip routes of administration of cisplatin in dogs. Cancer Treat Rep 1981;65:1055-1062.
16. Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;1:545-552.
17. Elit L, Oliver TK, Covens A, et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer 2007;109:692-702. (Pubitemid 46233230)